Multiple myeloma
Conditions
Interventions
1:CAR-T cell infusion
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70 years; 2. Patients whose estimated survival time is more than 12 weeks; 3. Patients diagnosed as multiple myeloma by physical examination, pathological examination, laboratory examination and imaging; 4. Patients who failed to receive chemotherapy for multiple myeloma; 5. Patients with multiple myeloma recurrence; 6. Alt, AST 50%; 8. Patients without serious liver, kidney, heart and other diseases; 9. Patients who failed to receive transplantation of autologous stem cells or allogeneic stem cells; 10. Patients who are not suitable for the conditions of stem cell transplantation or who give up the transplantation due to the limitations of the conditions; 11. Patients who can take blood from vein without other contraindications of leukocyte collection; 12. Patients who can understand and voluntarily sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, or women who have pregnancy plans within half a year; 2. Patients with infectious diseases (such as HIV, active tuberculosis, etc.); 3. Patients with active hepatitis B or C infection; 4. Feasibility evaluation and screening showed that the target lymphocyte transfection was less than 10% or the amplification was less than 5 times under the stimulation of CD3 / CD28; 5. The patients with abnormal vital signs and unable to cooperate with the examination; 6. Patients with mental or psychological diseases who can not cooperate with treatment and efficacy evaluation; 7. Patients with high allergic constitution or severe allergic history, especially those allergic to IL-2; 8. Patients who need anti infection treatment for systemic infection or local severe infection; 9. Patients with serious autoimmune diseases; 10. The doctor thinks there are patients who cannot be included in the treatment for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overoll response rate;Progression-free survival;Overoll survival;Safety; | — |
Countries
China
Contacts
Public ContactKailin Xu
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed